

**e-ASIA Joint Research Program (the e-ASIA JRP)  
Research Cooperation in the field of ‘Health Research’  
on the topic of  
‘Infectious Diseases and Immunology (including Antimicrobial Resistance)’  
13<sup>th</sup> Joint Call for Proposals to be submitted by 29 March 2024**

The e-ASIA Joint Research Program (hereinafter referred to as the “e-ASIA JRP”) aims to develop a vibrant and collaborative research community in Science and Technology, to promote innovation in the East Asian region, and to contribute to the region’s economic development. As part of the program, the Member Organizations of the e-ASIA JRP listed below have agreed to implement a joint call for proposals of multilateral cooperative research activities.

Participating Member Organizations (listed in alphabetical order)

- 1) Australia: National Health and Medical Research Council (NHMRC)
- 2) Indonesia: National Research and Innovation Agency (BRIN)
- 3) Japan: Japan Agency for Medical Research and Development (AMED)
- 4) Lao PDR: Ministry of Health (MOH)
- 5) Philippines: Department of Science and Technology (DOST-PCHRD)
- 6) Singapore: Agency for Science, Technology and Research (A\*STAR)
- 7) USA: National Institute of Allergy and Infectious Diseases (NIAID)

There are some additional requirements to fulfil the eligibility for the following organizations, please refer to below table:

<b>Member Organizations</b>	<b>Eligibility/Additional requirements</b>
(1) Australia: National Health and Medical Research Council (NHMRC)	1. NHMRC requires that collaborations must include a Lead PI or PI from at least one of the following participating member organisations: <ul style="list-style-type: none"> <li>• Indonesia: National Research and Innovation Agency (BRIN)</li> <li>• Lao PDR: Ministry of Health (MOH)</li> <li>• Philippines: Department of Science and Technology (DOST-PCHRD)</li> <li>• Singapore: Agency for Science, Technology and Research (A*STAR)</li> </ul> 2. Applications will only be accepted from NHMRC-approved Administering Institutions.

Member Organizations	Eligibility/Additional requirements
	<p>A list of NHMRC-approved Administering Institutions is available on <a href="#">NHMRC's website</a>.</p>
<p>(2) Indonesia: National Research and Innovation Agency (BRIN)</p>	<ul style="list-style-type: none"> <li>• Principal Investigator (PI) is an Indonesian citizen, a BRIN or non-BRIN researcher (university or other research institution, either from a business entity or community organization in Indonesia), civil servants or non-civil servants who has a doctoral education qualification and competency in conducting research with international partners.</li> <li>• One team member could only be participated maximum in 2 proposals (1 proposal as Principal Investigator and 1 proposal as member, or as member in both proposals).</li> <li>• The proposal must be written in English and submitted to Directorate of Research and Innovation Funding BRIN by email to <a href="mailto:dana-risnov@brin.go.id">dana-risnov@brin.go.id</a> (Subject email: CFP13-eASIA-Topic-Name of PI- Institution of PI) and using the provided template.</li> <li>• Application submission and correspondence may send by email to <a href="mailto:dana-risnov@brin.go.id">dana-risnov@brin.go.id</a>. The deadline for submitting your proposal is March 8th, 2024. You do not need to submit a proposal if you are merely a team member and not the Lead PI. Detail application process, links to guidance/ policy materials can be seen here <a href="https://pendanaan-risnov.brin.go.id">https://pendanaan-risnov.brin.go.id</a></li> </ul>
<p>(3) Japan: Japan Agency for Medical Research and Development (AMED)</p>	<p>1. AMED requires that collaborations must include a Lead PI or PI from at least one of the following participating member organisations:</p> <ul style="list-style-type: none"> <li>• Indonesia: National Research and Innovation Agency (BRIN)</li> <li>• Lao PDR: Ministry of Health (MOH)</li> <li>• Philippines: Department of Science and Technology (DOST-PCHR)</li> <li>• Singapore: Agency for Science,</li> </ul>

Member Organizations	Eligibility/Additional requirements
	<p>Technology and Research (A*STAR)</p> <p>2. Japan-based applicants are required to complete both e-mail submission to the e-ASIA JRP Secretariat and submission via the “e-Rad” system: (<a href="https://www.e-rad.go.jp/en/">https://www.e-rad.go.jp/en/</a>) by <b>17:00</b> (Japanese Standard Time) on <b>29th March 2024</b>.</p>
(4) Philippines: Department of Science and Technology (DOST-PCHRD)	<p>1. Filipinos with at least a master’s Degree in a relevant field, have proven research competence / track record, and employed in universities/colleges, research agencies/ institutes, hospitals, and other health related agencies are eligible to apply for the research grant.</p> <p>2. The proponent shall submit the following requirements online through the DOST Project Management Information System (DPMIS) (<a href="http://dpmis.dost.gov.ph/">http://dpmis.dost.gov.ph/</a>)</p> <p>3. Filipino researcher and implementing agency should comply with the eligibility requirements, especially on Item VI, of the DOST GIA Guidelines.</p>
(5) Singapore: Agency for Science, Technology and Research (A*STAR)	<p>1. Lead PI/PI must be an independent researcher from public sector research performers, namely the Institutes of Higher Learning (universities and polytechnics), A*STAR Research Institutes, as well as other non-defence-related public sector agencies (e.g., Ministries, Statutory Boards).</p> <p>2. Lead PI/PI must hold a primary appointment of at least 75% in a local publicly funded institution and salaried by the institution.</p> <p>3. Interested applicants to submit their proposals via e-mail to the e-ASIA JRP Secretariat, <u>copying the Point of Contact from</u></p>

Member Organizations	Eligibility/Additional requirements
	<p><u>A*STAR</u>, before the Closing Date on <b>29 March 2024</b>.</p>
<p>(6) USA: National Institute of Allergy and Infectious Diseases (NIAID)</p>	<ul style="list-style-type: none"> <li>• The U.S. PI and participants on the U.S. team may be foreign nationals (U.S. permanent residents or visa holders) but must reside in the United States for at least 50% of the award period. Graduate students on the U.S. team may be foreign nationals, but they must be enrolled in an accredited degree program at a U.S. institution during the period of their participation in the project.</li> <li>• Scientists, and other personnel working in U.S. federal government facilities, whose salaries are paid using direct U.S. federal funding, or personnel working under a contract supported by the U.S. federal government, may apply for this program; however, they are <b><u>not permitted</u></b> to receive funding or other support (e.g., travel) under this program. The federally funded U.S. PI and the affiliated U.S. federal agency participation must be in-kind or funding must be received by a collaborating non-federal U.S. institution, PI, and key personnel.</li> </ul>

**\*\*\*It is very important to read call guidelines carefully. It may affect the eligibility of the whole research team. Please see Appendix for more information on Eligibility/Additional requirements.\*\*\***

**I. Aim of Joint Call and Research Area**

The aim of the e-ASIA JRP 13<sup>th</sup> Call in the field of Health Research is to invite applications that will address health and medical issues in East Asia and neighboring regions and contribute to enhancing regional research capacity through multilateral collaboration. The topics identified for the e-ASIA JRP 13<sup>th</sup> Health Research Call pose a

considerable health threat to East Asian countries and are more broadly considered global health issues.

The focus of this joint call, within the “Health Research” program of the e-ASIA JRP, is on Infectious Diseases and Immunology (including Antimicrobial Resistance).

International collaborative research is critical to address infectious diseases that have global health impact, particularly emerging disease threats with pandemic potential, and the rise of antimicrobial resistant (AMR) pathogens. Available evidence suggests there is a disproportionate burden of multi-drug resistant AMR pathogens in low to middle-income countries, primarily due to under-resourced health systems.

This Health Research Call aims to identify biomedical and public health research opportunities, facilitate research collaborations, encourage sharing of knowledge, expertise and resources, and expand the global base of knowledge to respond to infectious disease priorities and challenges in the region.

Projects can be submitted from the full spectrum of health research from basic science, clinical, to applied public health research, that directly relate to human health. Please refer to the appendix for qualifying research by funding agencies, some of which fund specific types of research, e.g., basic research.

Possible research topics in infectious diseases and immunology include the following, **but are not limited to:**

- Intersections between chronic and infectious disease, including co- and multi-morbidities
  - common risk factors that aggravate the condition (e.g. tobacco, obesity)
  - immune response, inflammation, metabolism, and microbiome
- Novel vaccine immunogens for combatting emerging and re-emerging infectious diseases
- Utilization of microfluidics for discovery of antibody-based therapeutics against antimicrobial resistance
- Pandemic preparedness and response (e.g., surveillance, interventions, public awareness and prevention, vaccine development, climate change)
- Multi-OMICS approach towards discovery and innovation – Host immune responses to infectious diseases
- Novel antibody therapeutics and vaccine immunogens for combatting antimicrobial-resistant pathogens
- Effective public health infection control and prevention methods

### **Research Approach**

The e-ASIA JRP presents a research collaboration opportunity for researchers, as it offers access to funding and other resources to support multi-investigator research


engaging scientists in at least 3 countries in this call. To effectively utilize and maximize the unique opportunities provided through the e-ASIA JRP and to synergistically address infectious disease and immunology in East Asia, proposals that include the following integrated research approaches are strongly encouraged:

- Interdisciplinary research
- Training, mentorship, and career development of early-career (early-stage) investigators
- Communication, information, and data exchange
- Sample/data sharing and analysis
- Capacity building
- Community and stakeholders' engagement
- Commitment to long-term sustainability
- Establishment and maintenance of networks of collaborating institutions

Collaborative research projects, supported through this program, should be pursued through mutually beneficial partnerships and shared leadership that contribute to scientific innovation, research capacity and social applicability in the region. The study findings from the e-ASIA JRP projects should be disseminated to expand scientific knowledge and facilitate the utilization of the research results to enhance evidence-based environmental practice in East Asia and in other parts of the world.

## **II. Support/ Funding Modality**

In principle, each MO will support its own country's researchers in a selected research project in this joint call with the "Funding Modality" in the following table below. The duration of a selected research project will be three years (36 months), in total, from the start date. Details of conditions of support will vary by MO. Applicants shall refer to the Appendix for each MO's rules and regulations.



<b>Participating Member Organizations</b>	<b>Funding Modality</b>
(1) Australia: National Health and Medical Research Council (NHMRC)	New
(2) Indonesia: National Research and Innovation Agency (BRIN)	New, In-Kind
(3) Japan: Japan Agency for Medical Research and Development (AMED)	New
(4) Lao PDR: Ministry of Health (MOH)	In-Kind
(5) Philippines: Department of Science and Technology (DOST-PCHRD)	New
(6) Singapore: Agency for Science, Technology and Research (A*STAR)	In-Kind
(7) USA: National Institute of Allergy and Infectious Diseases (NIAID)	New, Re-Budgeting, and In-Kind

New: Each Member Organization will support a selected project by new funding

Re-budgeting: Funds already allocated to an existing project by each Member Organization will be reallocated to the e-ASIA JRP

In-kind: Each Member Organization of his/her country does not provide budget for a selected project. A researcher participating in a selected project will use funds that are already available, but no additional fund will be provided by each Member Organization from his/her country. In principle, at least one country must participate via “new” or “re-budgeting” funding modality. In other words, proposals cannot be accepted if all the applicants intend to participate through an “in-kind” basis.

**III. Application**

Each research team shall be led by a Principal Investigators (PI), and a consortium shall be led by a Lead PI specified among the PIs.

The Lead PI will be responsible for running and managing the project. The Lead PI will be the contact point with the e-ASIA JRP Secretariat on behalf of the whole consortium and is responsible for the administrative management of the complete project, should it be awarded supporting. In addition, the Lead PI is responsible for leading the project activities at his/her own institution. The Lead PI must be affiliated with an institution situated in one of the participating countries in this call.

Researchers from industry are encouraged to participate in the collaboration in accordance with domestic eligibility rules. PIs should contact the person noted in Section VI for information on their respective domestic eligibility rules.

In addition to the following common requirements, there are specific rules clarified by each Member Organization. All Lead PI must be aware and abide by all specific rules or eligibility requirements set out by their home country member organization, as well as any additional requirements set out by the partnering respective PI, member organizations. For specific rules by each Member Organization, please refer to the relevant National Appendix, the table on page 1, or consult the person noted in Section VI.

### III-1. Applicant/ Project Consortium

A project consortium must be consisted of at least three eligible research teams from at least three different participating countries listed above.

### III-2. Proposal Submission

Proposals must be submitted from the Lead PI by e-mail to the e-ASIA JRP Secretariat at the e-mail address specified below. Applications shall be written in English.

#### Deadline for Submission:

17:00 (Thai Standard Time, UTC+7) 29 March 2024

Please submit the proposal to:



Yukio Kemmochi, PhD (Mr.)

e-ASIA JRP Secretariat

E-mail: [easia\\_secretariat@jst.go.jp](mailto:easia_secretariat@jst.go.jp)

Note1: The e-ASIA JRP Secretariat will send a confirmation email to the Lead PI to confirm receipt of his/her proposal. In case the Lead PI does not receive a confirmation e-mail from the e-ASIA JRP Secretariat within one week, they should contact the e-ASIA JRP Secretariat at the address above. The e-ASIA JRP Secretariat does not assume any responsibility for delay or error in e-mail delivery.

Note2: Application forms sent by any method other than e-mail (such as post, fax or telex) will be rejected.

**< Important Notice to ALL PIs >**

Make sure to submit all necessary application documents requested by each Member Organization of your country, in addition to the application to the e-ASIA JRP Secretariat (submitted by Lead PI only), because each Member Organization may request applicants of its country to submit another form of proposals with another deadline date. Proposals shall satisfy both common requirements written in this call guideline and individual requirements requested by each Member Organization. A research team that does not satisfy individual requirements of the Member Organization of your country will not be deemed as eligible research team.

For individual requirements by each Member Organization, please refer to the Appendix or consult the person noted in Section VI.

The proposal shall include:

- a) Project description including how the collaboration will be carried out, with clear statements of what roles each country's researchers will play respectively in the project;
- b) Description of the expected outcomes of the proposed project, scientifically as well as in terms of relevance for industry and society;
- c) Description of the ongoing activities and specific advantages of each group respectively, which form the basis for the proposed joint project;
- d) Description of the expected value added from the proposed joint project, including how the competence, technology and other resources in each group complement each other;
- e) Description of how the project is expected to help strengthen multilateral research collaboration over the longer term;
- f) Description of the expected value added from the multidisciplinary approach in the proposed joint project; and
- g) Description of how the proposed joint project interacts with or impacts other comparable activities worldwide.

### III-3. Application Forms

Researchers should prepare the following application (proposal) forms in English ("E").

For further requirements by each Member Organization, researchers shall refer to the Appendix or shall consult each Member Organization of his/her country.

Form 1E Application outline (title, acronym, general description and proposed period of cooperative research project)

Form 2E Summary of the project

Form 3E Research leaders' information (their CVs\*)

Form 4E Research team (list of individuals committed to the cooperative research project in each country)

Form 5E Description of the cooperative research project

Form 6E Research networking plan

Form 7E Plan to nurture early career researchers

Form 8E Budget plan for the project

Form 9E Research infrastructures and funds from other sources

*\* The description of Curriculum Vitae (CV) from each PI shall include basic information on education, past and present positions, membership of relevant organizations /associations and a publication list in the past 5 years.*

In addition to the documents above, all projects must comply with ethical review and requirements of each Member Organization, especially for research activities related to human and animal subjects.

PIs shall refer to the Appendix for each Member Organization's ethical requirement.

## **IV. Evaluation**

### **IV-1. Evaluation Process**

A proposal will be evaluated at each relevant Member Organization of the project consortium, according to the evaluation criteria clarified in the following subsection.

Based on the results of the evaluation conducted at each Member Organization, a final decision will be made at the joint panel meeting among the participating Member Organizations, followed by approval at the e-ASIA JRP Board Meeting.

### **IV-2. Evaluation Criteria**

Proposals will be evaluated according to the following common e-ASIA JRP evaluation criteria, incorporated with evaluation criteria clarified by each Member Organization. For the evaluation criteria clarified by each Member Organization, please refer to the respective Appendix or consult each respective Member Organization.

#### 1) Regional Relevance of the Research

The research activity should contribute to:

- The advancement of scientific discovery;
- The development of science and technology in the region; and
- The resolution of significant relevant issues across the region.

## 2) Mutual Benefits of the Joint Research

Activities of mutual benefit to the collaborators and their institutions are desirable. Mutually beneficial in the sense that the projects utilize unique opportunities the e-ASIA JRP will provide that could not be achieved either through bilateral or individual research but only through multilateral cooperation.

## 3) Effectiveness of Exchange

The project should:

- Contain activities to nurture early career researchers through research activities;
- Contain activities to engage female researchers where strengthening capacity is needed; and
- Enhance research capacity in the region.

### IV-3. Notification of the Final Decision

The Lead PI will be notified the final decision by the e-ASIA JRP Secretariat as soon as the final decision is taken and approved by all Member Organizations in the e-ASIA JRP. (Approximate implementation of the notification: November to December 2024)

## **V. Project Implementation**

Project reporting will be in accordance with the respective Member Organization's rules. Please contact respective Member Organizations for more details.

In addition to the Member Organization's requirements, the consortia are expected to deliver Progress Reports and Final Reports to the e-ASIA JRP Secretariat, in English, including a description of their collaboration and a publishable summary of the project status. The Progress and Final Reports will be reviewed by the Board and Scientific Advisory Council. It is also encouraged that the project proactively disseminates its achievements to the public.

### V-1. Progress Report

In the middle of research period (i.e., after one and a half year), the lead PI shall promptly develop and submit an integrated progress report to the e-ASIA JRP Secretariat on the status of the joint research.

### V-2. Final Report

A final report shall be developed and submitted by the Lead PI to the e-ASIA JRP Secretariat within two months after the completion of the joint research period.

### V-3. Others

All the researchers/research institutions organizing a consortium are strongly recommended to conclude a Collaborative Research Agreement (hereinafter referred to

as “CRA”) to assure optimal understanding and coordination among the collaborating scientists working on each project before project starts. CRA should, with due respect to the researchers’ institutions and the Member Organizations’ intellectual property and data handling policy, include the treatment of intellectual property rights, handling of confidential information, publication of research results, warranty and indemnification, and access to and transfer of the relevant materials. Applicants shall refer to the Appendix for each Member Organization’s requirement.

#### VI. Contact information

Applicants should contact the following for information on each Member Organization’s eligibility rules or support conditions:

Also please refer to the Appendix for information of each Member Organization.

<b>Country: Member Organization</b>	<b>Contact Point</b>
(1) Australia: National Health and Medical Research Council (NHMRC)	NHMRC Research Help Centre Tel: +61 1800 500 983 (+61 2 6217 9451 for international callers) E-mail: <a href="mailto:help@nhmrc.gov.au">help@nhmrc.gov.au</a>
(2) Indonesia: National Research and Innovation Agency (BRIN)	Dr. Ajeng Arum Sari, Director National Research and Innovation Agency Phone: +62 811-1064-6771 E-mail: <a href="mailto:dana-risnov@brin.go.id">dana-risnov@brin.go.id</a>
(3) Japan: Japan Agency for Medical Research and Development (AMED)	Division of International Program Department of International Strategy, AMED Tel: +81 3 6870 2216 E-mail: <a href="mailto:e-asia@amed.go.jp">e-asia@amed.go.jp</a>
(4) Lao PDR: Ministry of Health (MOH)	Dr. Nilundone SENVANPAN Tel: +856 20 5566 9111 E-mail: <a href="mailto:nilundone.lun@gmail.com">nilundone.lun@gmail.com</a>
(5) Philippines: Department of Science and Technology (DOST-PCHR)	Mr. Vincent John H. Tumlos Tel: +632-837-7537 local 102 E-mail: <a href="mailto:yhtumlos@pchr.dost.gov.ph">yhtumlos@pchr.dost.gov.ph</a>

	Mr. Paul Ernest N. De Leon Tel: +632-837-7535 E-mail: <a href="mailto:pndeleon@pchrd.dost.gov.ph">pndeleon@pchrd.dost.gov.ph</a>
(6) Singapore: Agency for Science, Technology and Research (A*STAR)	Mr. Alvin Lau Office of Grants Administration, Innovation & Enterprise E-mail: <a href="mailto:oga_bilats@hq.a-star.edu.sg">oga_bilats@hq.a-star.edu.sg</a>
(7) USA: National Institute of Allergy and Infectious Diseases (NIAID)	Candice Beaubien, Office of Global Research Tel: +1 240 627 3098 E-mail: <a href="mailto:candice.beaubien@nih.gov">candice.beaubien@nih.gov</a>

Applicants should contact the following for general inquiries:



Yukio Kemmochi, PhD (Mr.)

e-ASIA JRP Secretariat / Japan Science and Technology Agency

Room 218 Innovation Cluster1 Building

National Science and Technology Development Agency (NSTDA)

111 Thailand Science Park, Phahonyothin Road

Khlong Nueng, Khlong Luang, Pathum Thani 12120 THAILAND

Tel: +66-2-564-7713

E-mail: [easia\\_secretariat@jst.go.jp](mailto:easia_secretariat@jst.go.jp)

**e-ASIA Joint Research Program (the e-ASIA JRP)  
Research Cooperation in the field of 'Health Research'  
on the topic of  
'Infectious Diseases and Immunology (including Antimicrobial Resistance)'  
13<sup>th</sup> Joint Call for Proposals to be submitted by 29 March 2024**

Information about each Member Organization (alphabetical order by country)

- 1) Australia: National Health and Medical Research Council (NHMRC)
- 2) Indonesia: National Research and Innovation Agency (BRIN)
- 3) Japan: Japan Agency for Medical Research and Development (AMED)
- 4) Lao PDR: Ministry of Health (MOH)
- 5) Philippines: Department of Science and Technology (DOST-PCHRD)
- 6) Singapore: Agency for Science, Technology and Research (A\*STAR)
- 7) USA: National Institute of Allergy and Infectious Diseases (NIAID)

## 1) Australia: National Health and Medical Research Council (NHMRC)

Applicants must be aware that NHMRC can only fund research into human health.

NHMRC can support a maximum of 4 applications. Applicants should note that NHMRC is only offering the funding modality of 'New' funding for this call.

### I. Eligibility

Eligibility is dependent on the following:

- (1) Projects require support from a minimum of three (3) e-ASIA member organisations including NHMRC, i.e. a research project must consist of an Australian research team collaborating with research teams seeking support from a minimum of two (2) e-ASIA participating member organisations in the relevant call.
- (2) NHMRC requires that collaborations must include a Lead PI or PI from at least one of the following participating member organisations:
  - a. Indonesia: National Research and Innovation Agency (BRIN)
  - b. Lao PDR: Ministry of Health (MOH)
  - c. Philippines: Department of Science and Technology (DOST-PCHR)
  - d. Singapore: Agency for Science, Technology and Research (A\*STAR)
- (3) Applications will only be accepted from NHMRC-approved Administering Institutions. A list of NHMRC-approved Administering Institutions is available on [NHMRC's website](#).

The Chief Investigator A (CIA) and Administering Institution must ensure applications meet all eligibility requirements, as set out in the e-ASIA call text and the Grant Opportunity Guidelines, at the time of submission and for the duration of peer review. Applications that do not meet eligibility requirements may be ineligible and may be excluded from further consideration.

It is the applicant's responsibility to verify the member organisation participation in respective calls, and any additional eligibility requirements specific to the member organisation. Partnering country applicants are required to submit their applications to their respective member organisation in line with the applicable funding organisation due dates.

NHMRC staff will not make eligibility rulings before an application is submitted.

### II. Support

NHMRC will support up to 4 applications, with a maximum budget of \$750,000 (AUD) per grant over three years.

## How to Apply

Australian researchers must submit an application to NHMRC (**through the Sapphire online grant management system**) AND to the e-ASIA JRP Secretariat to be considered for the NHMRC e-ASIA 2024 Joint Research Program. A copy of the research consortium's e-ASIA Common Application must be attached to the Sapphire application form. The application must address one (or more) of the research topics for the **\*Health Research** call.

### III. Evaluation

Applications for NHMRC e-ASIA 2024 Joint Research Program grant opportunity are assessed by peers against the weighted assessment criteria listed below.

- Health significance (20%)
- Scientific merit (20%)
- Design and methods (25%)
- Expertise of the research team (15%)
- Quality of the research partnership (20%)

### IV. Reporting

Administering Institutions are required to report to NHMRC on the progress of the grant and the use of grant funds. Applicants should note that e-ASIA JRP has additional reporting requirements and conditions specific to research funded under this grant opportunity, which includes the provision of:

- progress reports
- a final report

Further information is provided in the *NHMRC e-ASIA 2024 Joint Research Program Grant Guidelines* available on [GrantConnect](#).

### V. Contact Information

All enquiries should be directed to the NHMRC Research Help Centre

- Tel: +61 1800 500 983
- (+61 2 6217 9451 for international callers)
- E-mail: [help@nhmrc.gov.au](mailto:help@nhmrc.gov.au)

Refer to the [Research Help Centre webpage](#) for further information and opening hours



Australian Government

National Health and Medical Research Council

\*Edited on 19 December 2023 from "Food and Nutrition"

## 2) Indonesia: National Research and Innovation Agency (BRIN)

BRIN is supporting the following topics Health Research:

Infectious Diseases and Immunology (including Antimicrobial Resistance)

The following funding modalities will be supported:

- New
- In-kind

### I Eligibility for Indonesian Applicants

- Principal Investigator (PI) is an Indonesian citizen, a BRIN or non-BRIN researcher (university or other research institution, either from a business entity or community organization in Indonesia), civil servants or non-civil servants who has a doctoral education qualification and competency in conducting research with international partners;
- Team members may come from across institutions, universities, and/or other research institutions from business entities or independent research institutions;
- Both Principal Investigator and research team members have an experience and expertise relevant to the proposed research and proven by evidence of a track record (portfolio) of research activities;
- One team member could only be participated maximum in 2 proposals (1 proposal as Principal Investigator and 1 proposal as member, or as member in both proposals).

### II Support

BRIN will support up to 5 applications. Research funding can be implemented for a maximum period of 3 (three) years based on the results of evaluations each year with a maximum amount of IDR 1,000,000,000 per project/year (including researcher mobility and infrastructure sharing).

List country specific eligible costs:

- Purchase/procurement of chemicals/consumables such as raw materials or production components;
- Honorarium for field workers;
- Domestic travel, directly related to the research activities;
- Indonesian grant could not be used for equipment;
- Mobility of Indonesian and foreign researchers and experts refers to the BRIN researcher mobility scheme (post-doctoral and/or visiting researcher). The Researcher Mobility Scheme is restricted to BRIN researchers only. For Indonesian researchers who will use the Researcher Mobility Scheme, they must engage the BRIN research group.

Please adjust the RIIM Kolaborasi guidelines as a reference for funding from Indonesia.

### **III How to Apply**

The proposal must be written in English and submitted to Directorate of Research and Innovation Funding BRIN by email to [dana-risnov@brin.go.id](mailto:dana-risnov@brin.go.id) (Subject email: CFP13-eASIA-Topic-Name of PI-Institution of PI) and using the provided template. All documents must be complete and original. The awardee selected proposed funding will be subject to assessment by BRIN reviewer. The amount of funds will be determined through the evaluation process by the reviewer assigned by BRIN. Shortlisted participants would be invited to give presentations if needed.

Application submission and correspondences may send by email to [dana-risnov@brin.go.id](mailto:dana-risnov@brin.go.id). The deadline for submitting your proposal is March 8th, 2024. You do not need to submit a proposal if you are merely a team member and not the Lead PI.

Additional application materials are required to be submitted directly to BRIN (email to: [dana-risnov@brin.go.id](mailto:dana-risnov@brin.go.id)) after the awardee list has been announced by the e-ASIA Secretariat of the Joint Research Program (the e-ASIA JRP).

Detail application process, links to guidance/policy materials can be seen here <https://pendanaan-risnov.brin.go.id>.

### **IV Evaluation**

Once BRIN has approved the proposal, PI must submit it to the e-ASIA Secretariat for assessment and evaluation based on the general evaluation criteria of the e-ASIA JRP. Applications submitted to the e-ASIA Secretariat will be reviewed according to the published e-ASIA JRP evaluation process and criteria.

### **V Reporting**

- The Indonesian PI shall promptly submit a progress report on the status of joint research to BRIN, in accordance to the second term disbursement.
- After completion of the period of joint research, the Indonesian PI shall submit within a month a final report on the results of the joint research to BRIN.

#### **Ethical Clearance and Foreign Research Permit**

Researchers and Foreign Parties have to obtain a research permit. To obtain a research permit, Researchers and Foreign Parties must apply for Research Ethical Clearance and foreign research permit request. This application is done through the Research Ethical Clearance information system (<https://klirensetik.brin.go.id/>)

#### **Material Transfer Agreement**

Awardee agree that any tangible research materials required to be taken from the Republic of Indonesia for research purposes of the approved collaborative project shall be transferred through a Material Transfer Agreement (MTA) between concerned research organizations in strict compliance with the legislation of the Republic of Indonesia.

### Intellectual Property

In the event of joint research cooperation, it is the responsibility of the respective member of the collaborating project partners to determine in advance how any exploited IP will be divided amongst the partners in accordance with the prevailing laws and regulations of the respective countries of the institutions Participants and the institutions' policies and procedures. Details of this agreement shall be included in the collaborative agreement.

### Genetic Resources and Traditional Knowledge

1. The Parties recognize the importance of the protection of genetic resources and traditional knowledge associated with genetic resources (hereinafter referred to as the "GRTK"). Awardee to carry out any research activities in accordance with the provisions of International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) FAO, the Convention on Biological Diversity (CBD) and other international agreements, particularly taking into account the principle of prior informed consent and of fair and equitable benefit sharing.
2. Details regarding the management of GRTK shall be included in the Collaborative Agreement of any collaborative projects.

### Data and Material Management

Data and information resulting from the research activities shall be submitted and stored at the Indonesian national repository (Repositori Ilmiah Nasional) through the page <https://rin.brin.go.id/> in accordance with applicable laws and regulations;

Material or specimens resulted from the research activities must be lodged with the BRIN cq. Directorate of Scientific Collection Management.

## **VI Contact Information**

Dr. Ajeng Arum Sari

Director of Research and Innovation Funding

National Research and Innovation Agency

Phone: +62 811-1064-6771

E-mail: [dana-risnov@brin.go.id](mailto:dana-risnov@brin.go.id)

### **3) Japan: Japan Agency for Medical Research and Development (AMED)**

AMED can support a maximum of three (3) applications. The following funding modalities will be supported:

- New

Japan-based applicants must read and accept the following AMED-specific conditions for this program. Please refer to the information on the following website:

[https://www.amed.go.jp/koubo/20/01/2001B\\_00075.html](https://www.amed.go.jp/koubo/20/01/2001B_00075.html)

For project proposals in which Japan-based applicants hope to receive funding from AMED, it is encouraged that more than two countries participating in the project do so using either the “New” or “Re-budgeting” funding modality.

#### **I. Eligibility for Japan-based applicants**

The Japan-based PI must be personally affiliated with a domestic research institution and conduct research there. Domestic research institutions on the Japanese side are universities, independent administrative institutions, national/public testing and research institutions, specially authorized corporations, public-service corporations and enterprises, etc. that must satisfy predetermined requirements specified by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan.

Any individual who satisfies any of the following conditions is also eligible to apply as a Japan-based PI.

- i) Researchers holding citizenship other than Japanese, who belong to a Japanese domestic research institution.
- ii) Researchers who are not currently affiliated with a particular research institution, but who will be affiliated with a Japanese domestic research institution and able to conduct research there if selected as a Japan-based PI.
- iii) Japanese researchers currently residing overseas who will be affiliated with a Japanese domestic research institution and able to conduct research there if selected as a Japan-based PI.

Japan-based PIs must be able to take responsibility for the duties of the entire project for the full duration of the joint research project.

Japan-based researchers from industry are eligible to participate in the joint research project in the Japan-based Team.

## II. Support

### II-1. Budget for Cooperative Research Projects

The budget for a project may differ each year, depending on the content of activities, but the total budget for the Japanese researcher over a full 3-year period (i.e. 36 months) should be up to 22.5 million Japanese Yen as direct expenses. 30% of direct expenses will be provided as overhead expenses. According to the budgetary limitations for this program, the amounts will be adjusted each year.

### II-2. Details of Support

This program is designed to support additional expenses related to cooperation by a Japan-based researcher with their counterparts, such as expenses for travel and/or conducting seminars/symposia. A precondition for applying to this Joint Call is that the main research infrastructure is already in place for each research group. The duration of a co-operative research project shall be no longer than three (3) years (thirty-six (36) months) in total from the start date.

### II-3. Eligible costs

Research grants will be awarded in line with standard AMED policy. Funding provided within this call is intended to enhance the capacity of the applicants to collaborate. Funding will therefore be provided mainly in support of collaborative activities but may also cover some of the local research expenses that are necessary for the collaboration.

#### 1. Direct Expenses:

- i) Travel expenses: In principle, travel expenses should be based on the rules of the institution to which the Principal Investigator (hereinafter referred to as the PI) belongs.
- ii) Expenses for holding symposia, seminars and meetings.
- iii) Expenses for facilities, equipment and consumables.
- iv) Expenses for personnel: Stipend or salary for a PhD student, or salary for a post-doctoral fellow, or Japan-based researchers including the PI.

v) Other: Expenses for creating software, renting or leasing equipment, transporting equipment, expenses for buyout costs, etc.

2. Overhead expenses shall be 30% of direct expenses.

3. Expenses not covered/funded by the program:

i) Expenses relating to the acquisition or rental of real estate or construction of buildings or other facilities.

ii) Expenses related to the procurement of major equipment.

iii) Expenses related to dealing with accidents or disasters occurring during the co-operative research period.

iv) Expenses unrelated to the implementation of this co-operative research project.

For more details about salaries for Japan-based PIs and buyout costs, please visit the following website: [https://www.amed.go.jp/keiri/youshiki\\_itaku.html](https://www.amed.go.jp/keiri/youshiki_itaku.html) (in Japanese only)

#### II-4. Conclusion of contracted R&D agreement

For each funded R&D project, a one-fiscal-year contracted R&D agreement shall be concluded between the research institution implementing the R&D project and AMED, in accordance with the principles of the accounting period of the national government. Successful applicants shall receive detailed information from AMED following project selection.

#### II-5. Collaborative Research Agreement

For each funded R&D project, a Collaborative Research Agreement (CRA) MUST be concluded among the institutions with which the collaborating researchers are affiliated. The CRA should include conclusions of discussions among Parties which are entitled to intellectual property arising as a result of the research collaboration, and Institutions concerned, on issues regarding treatment of research information brought by researchers involved for the implementation of the research collaboration, research achievements resulting from the research collaboration, and handling of intellectual properties. The CRA so concluded shall be shared among the Parties. A sample CRA can be found on the following website:

<https://www.the-easia.org/jrp/documents.html>

### III. How to Apply

Please note that Japan-based applicants are required to complete both e-mail submission to the e-ASIA JRP Secretariat and submission via the “e-Rad” system. Applications will be considered ineligible if the proposal documents are not submitted by the deadline through both submission systems.

### III-1. Application Forms

Form J is only for Japan-based applicants and should be prepared in Japanese (“J”) in addition to the common application form in English.

Form J is available from the AMED website:

[https://www.amed.go.jp/koubo/20/01/2001B\\_00075.html](https://www.amed.go.jp/koubo/20/01/2001B_00075.html) (in Japanese only)

### III-2 Submission of Application Forms by Applicants

Proposals must be submitted by e-mail to the e-ASIA JRP Secretariat.

Japan-based applicants must also submit a project title, a summary of the project, and detailed budget information in Japanese with their application forms through the “e-Rad” online application system (<http://www.e-rad.go.jp/index.html>) by **17:00** (Japanese Standard Time) on **29th March 2024**.

Application to the program is not complete at the point when the PI submits the application to their affiliated research institute via e-Rad. Be sure to undergo procedures to obtain approval of the submission of the application from your affiliated research institute.

## IV. Evaluation

The program evaluation committees consisting of relevant experts will evaluate all proposals. Based on the results of their evaluations, a common decision will be made jointly by the participating Member Organizations regarding selection of proposals for funding.

### IV-1. Evaluation Criteria

#### 1. Compatibility with the program’s purpose

- Is the project compatible with the program’s purpose and objectives, etc.?

#### 2. Scientific/technological significance and advantage

- Are the current technological level and previous performance of applicants sufficient?
  - Does the project proposal have originality, novelty, and innovativeness?
  - Does the project contribute to the advancement of the field of medicine?
  - Does the project contribute to the development of new technologies?
  - Does the project respond to a societal need?
  - Is the project compatible with national policies regarding R&D in the field of medicine?
3. Appropriateness of the plan
- Are the overall content and objectives of the plan clear?
  - Are the plans for each fiscal year detailed and feasible?
  - Is the project plan in compliance with laws and ordinances related to bioethics and safety measures?
4. Implementation system
- Has an appropriate R&D system centered on each applicant been organized?
  - Has a sufficient collaboration network been constructed?
  - Are the comparative efforts of the applicants appropriate?
  - Is there any unreasonable duplication/excessive concentration of effort?
5. Costs
- Are the breakdown of costs and spending plan appropriate?
6. Items prescribed under the program and items that should be considered comprehensively
- Does the project contribute to the development of science and technology in the ASEAN region? (Regional Relevance of the Research)
  - Does the project contribute to solving significant and relevant issues across the ASEAN region? (Regional Relevance of the Research)
  - Is there a unique opportunity for research/outcomes that could not be achieved either through bilateral or individual research but only through multilateral cooperation? (Mutual Benefits of the Joint Research)
  - Does the project contain activities to nurture early career researchers through research activities? (Effectiveness of Exchange)
  - Does the project enhance research capacities in the ASEAN region? (Effectiveness of Exchange)

After completing the projects, final evaluation will be performed based on the final reports by the program evaluation committees in AMED.

## **V. Reporting**

### **V-1. Progress Report to AMED**

At the end of each fiscal year, the Japan-based PI shall promptly submit to AMED an annual progress report on the status of research activities and exchange, and the institution with which the PI is affiliated shall promptly submit to AMED a financial report on research expenses.

### **V-2. Final Report to AMED**

Final reports should be submitted within four (4) months of completion of the research period.

The institution with which the PI is affiliated shall submit a financial report on research expenses to AMED within two months after termination of contract.

## **VI. Contact Information**

Division of International Program

Department of International Strategy

Japan Agency for Medical Research and Development (AMED)

TEL: +81 (0)3-6870-2216    E-mail [e-asia@amed.go.jp](mailto:e-asia@amed.go.jp)



Japan Agency for Medical Research and Development

#### **4) Lao PDR: Ministry of Health (MOH)**

##### **Funding Modality**

In-kind

##### **Contact Information**

Dr. Nilandone SENVANPAN

Parasitology Control Division;

Department of Communicable Disease Control;

Ministry of Health, Lao PDR

P/M: +856 20 5566 9111

E-mail: [nilundone.lun@gmail.com](mailto:nilundone.lun@gmail.com)

## 5) Philippines: Department of Science and Technology (DOST-PCHR)

### I. Review Procedures

Approval of proposals for research grants will be based on a multi-level review process.

1. In-house screening in terms of alignment to the research priorities, duplication, and completeness of requirements.
2. Technical review and scoring by external consultants (Technical Panel) based on the following criteria:

Relevance & Sensitivity	Alignment to national S&T priorities, strategic relevance to national development and sensitivity to Philippine political context, culture, tradition and gender and development.
Technical/Scientific	Merit Sound scientific basis to generate new knowledge or apply existing knowledge in an innovative manner.
Financial Feasibility	Financial viability of the undertaking with proponent's and institutional capacity to manage R&D funds vis-à-vis the proposed work plan and budget.
Proponent's / Institutional Capacity	Good track record or CV with proven competence to implement and complete the R&D program / project within the approved duration and budget.
Program Contribution	How much the proposal will contribute to the overall achievement of the program? Other potential socio-economic, environmental, and health impact.

3. Final approval by the PCHR Governing Council or the PCHR Executive Director depending on the recommended total budgetary requirement of the proposal.
4. In each stage of the review process, the proponent may need to revise the proposal on the basis of the recommendations of the reviewers. The review process will take 40 working days provided that all the requirements had been submitted.

## II. Who may apply

Filipinos with at least a Master's Degree in a relevant field, have proven research competence / track record, and employed in universities/colleges, research agencies/institutes, hospitals, and other health related agencies are eligible to apply for the research grant.

## III. How to apply

The proponent shall submit the following requirements online through the DOST Project Management Information System (DPMIS) (<http://dpmis.dost.gov.ph/>):

- Project Proposal following the DOST Detailed Proposal Form (downloadable from the DOST DPMIS website).
- Work plan Schedule (Gantt Chart of Activities)
- Proposed Line-Item Budget (LIB) (DOST-GIA LIB Form)
- Counterpart Funding of Implementing Agency
- Endorsement of Agency Head
- Curriculum Vitae of Proponent(s)
- Duties and Responsibilities of each Project Personnel
- For proposals with human subjects:
  - Informed Consent Form
  - Case Report Form, if applicable
- Endorsement Letter from Agency Ahead addressed to:

The Executive Director  
Philippine Council for Health Research and Development  
Department of Science and Technology  
Bicutan, Taguig City

DOST-PCHRD shall also require the proponent to submit the following documents before the start of project implementation:

- Biosafety Clearance, if applicable
- Animal research permit, if applicable
- Bureau of Animal Industry Clearance, if applicable
- Ethics Clearance (for studies involving human subjects)

## IV. Funding Support Available

DOST-PCHRD will support 2 projects under this Call and allocate up to **87,000 USD (PhP 5,000,000)** for each research project for a duration of three years.

Deadline for online submission will be on or before **03 April 2024, 5:00 PM** (Philippine Standard Time).

**Important Notes:**

1. Application and funding will be governed by the DOST Grants-in-Aid Guidelines and its amendments for Filipino researchers.
2. Additional and specific requirements may be required on a **separate local call** to be issued and published by the DOST-PCHRD. Filipino researchers are advised to anticipate this local call for their guidance.
3. Online submission will be through the DOST DPMIS website only. Submission through emails will not be accepted.

**V. Contact Information**



Mr. Vincent John H. Tumlos

Department of Science and Technology (DOST)

Philippine Council for Health Research and Development (PCHRD)

Tel: +632-837-7537 local 102

E-mail: [vhtumlos@pchrd.dost.gov.ph](mailto:vhtumlos@pchrd.dost.gov.ph)

Mr. Paul Ernest N. De Leon

Department of Science and Technology (DOST)

Philippine Council for Health Research and Development (PCHRD)

Tel: +632-837-7535

E-mail: [pndeleon@pchrd.dost.gov.ph](mailto:pndeleon@pchrd.dost.gov.ph)

## 6) Singapore: Agency for Science, Technology and Research (A\*STAR)

A\*STAR's official call announcement:

<https://www.a-star.edu.sg/Research/funding-opportunities>

### **I. Eligibility for Singapore-based applicants**

1. Lead PI/PI must be an independent researcher from public sector research performers, namely the Institutes of Higher Learning (universities and polytechnics), A\*STAR Research Institutes, as well as other non-defence-related public sector agencies (e.g., Ministries, Statutory Boards).
2. Lead PI/PI must hold a primary appointment of at least 75% in a local publicly funded institution and salaried by the institution.

### **II. Support**

#### **II-1. Funding Principles**

For the e-ASIA 13<sup>th</sup> Call in the field of Health Research, Singapore-based applicants will be participating via an in-kind modality.

### **III. Application**

Interested applicants to submit their proposals via e-mail to the e-ASIA JRP Secretariat, copying the Point of Contact from A\*STAR identified below, before the Closing Date on 29 March 2024.

Note: applications must be endorsed by the applicants' Host Institution(s) prior to submission.

## **IV. Evaluation of Project Proposals**

Proposals will undergo a peer review round before proceeding to a joint panel evaluation with other Member Organisations for final funding recommendation. Subsequently, selected proposals will be approved at the e-ASIA JRP Board Meeting.

### **IV-1. Evaluation Criteria**

In addition to the evaluation criteria set by the e-ASIA JRP (see IV-2. Evaluation Criteria in the Call Guideline), the following evaluation criteria will be applied to each Singapore-based application:

1. Novelty and originality of the proposed idea or concept
  - Are the aims original and innovative?
  - Does the project employ novel approaches or methods and/or will generate novel products or processes?
  - Is the proposed methodology feasible/viable?
2. Quality of Science
  - Would the outcomes of the project lead to scientific excellence in the proposed field of research?
3. Competitive / comparative advantage, potential for commercial exploitation
  - How competitive is the proposal internationally?
4. Capability of the research performers to conduct the research
  - Does the research performer/team possess the necessary expertise and competences to conduct the research successfully?
5. Collaborative advantage of the Lead PI/PI and academic/industry collaborator(s)
  - Are there synergies between the Lead PI/PI and the academic and industry partners in this collaboration?
  - Do all the partners bring in significant and/or unique contributions to the research?
  - Does the project contribute to and benefit from an equitable and balanced cooperation?

## **V. Reporting**

### **V-1. Progress report to A\*STAR**

Each awarded project will be evaluated and assessed for progress to ensure that the proposed milestones and deliverables can be achieved. Successful grant applicants will be required to submit an annual progress report to A\*STAR via the Integrated Grant Management System (IGMS).

#### VI-2. Final report to A\*STAR

Singapore-based applicants are required to submit a final report on the results of the joint research within three (3) months following the end of the project term.

### **VI. Contact Information**



Mr. Alvin Lau

Office of Grants Administration, Innovation & Enterprise

Agency for Science, Technology and Research (A\*STAR)

E-mail: [oga\\_bilats@hq.a-star.edu.sg](mailto:oga_bilats@hq.a-star.edu.sg)

## 7) USA: National Institute of Allergy and Infectious Diseases (NIAID)

The NIAID mission is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases, including the research response to emerging public health threats.

For the e-ASIA JRP 13<sup>th</sup> Call on Infectious Diseases and Immunology, NIAID funding may be requested to support basic, clinical, and applied biomedical research focused on infectious diseases and immunology. Requests can be within a broad scope of biomedical/behavioral health research including emerging and re-emerging infectious diseases, as well as antimicrobial resistance (AMR), and research collaborations aimed towards pandemic preparedness and research response. Projects may consider multiple approaches to pandemic preparedness, including pathogen-specific work (particularly those in the region), platform-based technologies, and prototype-pathogen efforts (working on solutions within viral families and genera); as well as inter-disciplinary approaches to address infectious disease, (including vector-borne, waterborne, foodborne, zoonotic, respiratory, fungi, and antimicrobial resistance) allergic and immunologic diseases.

Applications requesting NIAID funding to support research that falls outside these areas will not be considered eligible for NIAID funding. For example, applications focused on health care quality assurance or similar issues would not be eligible for NIAID funding.

### **Application Materials**

No additional application materials are required to be submitted directly to NIAID. Only the e-ASIA JRP application submitted directly to the e-ASIA Secretariat is required and will be reviewed and evaluated according to the common e-ASIA JRP evaluation criteria (refer to Section [IV-2](#)) and the [additional evaluation criteria listed below](#). Please see below for more information.

### **Eligibility**

The U.S. PI and participants on the U.S. team may be foreign nationals (U.S. permanent residents or visa holders) but must reside in the United States for at least 50% of the award period. Graduate students on the U.S. team may be foreign nationals, but they must be enrolled in an accredited degree program at a U.S. institution during the period of their participation in the project.

Scientists, and other personnel working in U.S. federal government facilities, whose salaries are paid using direct U.S. federal funding, or personnel working under a contract supported by the U.S. federal government, may apply for this program; however, they are **not permitted** to receive funding or other support (e.g., travel) under this program. The federally funded U.S. PI and the affiliated U.S. federal agency participation must be in-kind, or funding must be received by a collaborating non-federal institution, PI, and key personnel.

### **Additional Evaluation Criteria**

**Research Plan:** How well the individual elements of the project plan fit with the overall project goals.

**Technical Merit:** The technical soundness of the proposed work, the project's management plan, and adequacy of the resources available, both technical and financial.

**Research Impact:** The probability that the project will result in new knowledge in one or more research fields or have a positive impact on health of the population in the East Asia region or/and all over the world.

### **Budget and Allowable Costs**

The maximum total award is up to **\$100,000** U.S. Dollars (USD) disbursed over three years. Utilizing funds from NIAID, the U.S. institution will receive a cost- reimbursable grant (fixed obligation award) from CRDF Global, pending the submission and acceptance of all necessary approvals and documentation (e.g., IRB approval, award agreement, animal subject review, etc.).

CRDF Global will communicate directly with the U.S. PIs and support expenses for the U.S. teams from universities and non-profits with the exception of large- scale equipment purchases that cost over \$10,000 USD. U.S. team applications may propose utilizing some of the requested funding to support foreign partners, but the allowed maximum budget still cannot exceed the amount described in the preceding paragraph. U.S. federal government agencies and U.S. **\*applicants** from for profit companies may apply in partnership with other U.S. or regional scientists but are not permitted to receive funding under this program.

i. Funding may be requested for the following expenses:

- (1) Labor
- (2) Equipment, Supplies and Services
- (3) Travel
- (4) Indirect Costs (IDC). Applicants (primary and secondary collaborators, including those from foreign institutions) may request indirect costs/overhead expenses on all direct costs except for equipment (over \$5,000), capital expenditures, rent, student tuition, participant support costs<sup>[1]</sup> and sub-awardees expenses (after the first \$25,000). Total direct costs minus these items are considered the modified total direct cost (MTDC) amount for which the IDC rate should be applied. IDCs combined with the total direct costs cannot exceed the funding total allowed to request. Below are helpful calculations:

- **IDC \$ = IDC% x MTDC = \$**

**\* Edited on 20 December 2023 from "teams"**

- **Maximum Total Sub-Team budget** = total direct costs \$ (including MTDC) + IDCs \$

Foreign Institutions may **not request more than 8%** of the modified total direct costs in IDCs. U.S. institutions with a Negotiated Indirect Cost Rates Agreement (NICRA) may request up to their approved NICRA rate. Documentation for these rates should be provided in the budget narrative if the institution requires this payment. U.S. institutions without a NICRA may **not request more than 10%** in IDCs.

---

<sup>[1]</sup> Participant Support costs include stipends or subsistence allowances, travel allowances and registration fees paid to or on behalf of participants or trainees (but not employees) in connection with meetings, conferences, symposia or training projects, scholarships/fellowships.

Recognizing the limited funding available for these small projects and the goal to achieve maximum scientific outcomes, applicants are encouraged to provide cost shares. Awardees with a Negotiated Indirect Cost Rate Agreement (NICRA) from a U.S. federal cognizant agency may claim their NICRA, however, they are encouraged to provide a cost share to cover the difference in cost rate, so that the applied Indirect Cost rate does not exceed 8% of the award's modified total direct costs. Eligible cost shares must be verifiable through appropriate documentation provided by the awardee and should be described within the budget narrative. Cost shares should be:

- Verifiable through appropriate documentation provided by the awardee
- Necessary and reasonable for the accomplishment of project objectives
- Allowable costs under this program

Not paid by the U.S. government under another award, except where the Federal statute authorizing a program specifically provides that Federal funds made available for such a program can be applied to matching or cost sharing requirements of other U.S. government-funded programs.

Examples of cost shares that may be included in the proposal:

- **Salary:** (including fringe benefits) of any team member essential to the project. Salary and fringe rates should be listed separately for each team member in the cost share budget.
- **Consultant services:** Labor and fringe rates for third parties providing volunteer services towards the project may be counted as cost sharing or matching if the service is an integral and necessary part of the project. Rates for third-party volunteer services must be consistent with those paid for similar work by the non-Federal entity. In those instances, where the required skills are not found with the awardee, rates must be consistent with those paid for similar work in the labor market.
- **Equipment/Supplies:** Donated equipment, office supplies, or laboratory supplies. Value for these items must be assessed at fair market value of the property at the time of donation.
- **Travel:** For travel deemed necessary and reasonable to the project, the awardee may cost share appropriate travel expenses, including:

- **Airfare:** Lowest cost economy airfare and compliant with the Fly American Act Guidelines.
- **Lodging:** Not to exceed applicable domestic or international U.S. government per diem rates
- **Meals and Incidentals:** Not to exceed applicable domestic or international U.S. government per diem rates
- **Ground Transportation:** Necessary local travel, such as taxis, rental cars, or mileage reimbursement on use of personal vehicles in accordance with the U.S. government allowance for Privately Owned Vehicles (POV)

### **Contact Information**



Candice Beaubien, MPH  
Team Lead - Americas, Caribbean, Asia, and Pacific (ACAP) Team  
Regional Officer-Asia and the Pacific  
Office of Global Research (OGR)  
National Institute of Allergy and Infectious Diseases (NIAID)  
National Institutes of Health (NIH)  
Department of Health and Human Services  
5601 Fishers Ln MSC 9802  
Bethesda, MD 20892-9802 [For courier deliveries: 20852]  
Phone: +1 (240) 627-3098  
Email: [candice.beaubien@nih.gov](mailto:candice.beaubien@nih.gov)

**General inquiries**

Yukio Kemmochi, PhD. (Mr)

e-ASIA JRP Secretariat / Japan Science and Technology Agency

Room 218 Innovation Cluster1 Building

National Science and Technology Development Agency (NSTDA)

111 Thailand Science Park, Phahonyothin Road

Khlong Nueng, Khlong Luang, Pathum Thani 12120 THAILAND

Tel: +66-2-564-7713

E-mail: [easia\\_secretariat@jst.go.jp](mailto:easia_secretariat@jst.go.jp)